What is the latest conversations and articles BUZZING IN OUR EARS:
University of Connecticut Health Center (UCHC):
UCONN Today April 5, 2012 article by Chris DeFrancesco entitled
Health Center Prepares for Parking Changes
prepares for June 2012 Lots G, I and L updating as well as valet and shuttle bus changes. While not appearing to directly affect Academic Research Building parking Lot A for now, traffic patterns and congestion may impact arrival/ departure times, so plan accordingly.
Herbert L. Bonkovwski, M.D. contributed to the article
Abstract: Weight Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial published 5\14\09 in Gastroenterology concludes that
"Insulin resistance, histological features of fatty liver disease, and weight change were associated with outcomes of chronic hepatitis C. Improvement in these weight related factors might modify disease progression."
Tattoos ... and the Risk of Hepatitis
by T. Colleen Morgan was published in the Republican-American, September 23, 2004 and Dr. Wu included statements that "...Any procedure that involves piercing the skin runs a risk that certain infectious viruses will spread... tattooing 'a risky behavior' even when tattoo parlors take precautions to guard against it... If the ink is used only once and it is sterile and the needle is sterile and the proper technique is used, the risk is low.... It's a small percentage of tattoos (that transmit hepatitis), and it's usually kids who do it on their own. They tattoo themselves or each other, like being blood brothers. I think, in this country, most of the tattoo places are pretty careful... Hepatitis C is a greater concern than hepatitis B...the C Strain is also more common... Someone acutely affected with hepatitis B can get it and it resolves on its own without any treatment in 80 to 85 percent of cases, which means only 15 to 20 percent of the cases will go on to be a chronic disease or even need treatment. In contrast, about 80 to 85 percent of patients with hepatitis C acutely will go on to have the chronic disease, and there is no vaccine for it so we can't be protected..."
New England Journal of Medicine
abstract "Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon" includes HALT-C trial investigative work from Dr. Herbert L. Bonkovsky that concluded "...long-term therapy with peginterferon did not reduce the rate of disease progression in patients with chronic hepatitis C and advanced fibrosis, with or without cirrhosis, who had not had a response to initial treatment with peginterferon and ribavirin..."
From the Hepatitis C Support Project (HCVadvocate):
Hepatitis Support Project bi-monthly publication Hepatitis Journal Review includes a
entitled Persistent HCV after SVR in review of a May 2009 Hepatology article and discuss investigators conclusion "HCV persisting at very low levels long after therapy-induced resolution of chronic hepatitis C can remain infectious."
Dr. Raymond Koff, clinical professor of medicine at the University of Connecticut School Of Medicine,
at October 16, 2008 HFI presentation "Hepatitis C: The Hidden Epidemic" at New York Academy of Science